TP53 and acute myeloid leukemia: However, the outcomes with this approach are suboptimal in patients with adverse-risk cytomolecular features, where median overall survival (OS) is 6–8 months, with even worse outcomes in those with TP53-mutated AML or treated secondary AML [5, 10, 11].